A teen with Duchenne reports improvement on Solid’s gene therapy, and investors take notice

A 14-year-old boy with Duchenne muscular dystrophy has regained some strength and function in his muscles following treatment with an experimental gene therapy from Solid Biosciences, the boy’s father tells STAT.

And although it’s just a single case report — with additional details being gleaned from the father’s posts in a closed Facebook group — it’s playing a part in easing investor concerns about the safety of the Solid treatment.